Kintor gt20029

This is just my advice to the guys that are depressed about hair loss, unfortunately, it’s something we can’t control (some what) I see some many young guys out here sad cause of hair loss at a young age (including me) mine started when I was 21 and had been falling off ever since (now 25) I was very self conscious about it not gonna lie but I realized that I was sad over something that ... As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. ... Kintor Pharma's products pipeline consists of innovative, small-molecule ...Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 Aug 09, 2022 · Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China. August 9, 2022, 9:00 AM UTC. Share this article. Copied. Feb 03, 2022 · GT20029 is an a topical androgenreceptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor ... Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021Nah bro I wouldn't say that. Both of the drugs are in development at the same time. Pyrilutamide is further along in development. Check out their website and search the sub for gt20029 it's a topical androgen degrader.SUZHOU, China, July 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in ChinaOn February 2, 2021, Kintor announced that an investigational new drug application (IND) for the drug GT20029 has been approved by the NMPA of China (equivalent to the FDA) for the indications of androgenic alopecia and acne vulgaris. GT20029 is a new advanced form of an anti-androgen called a PROTAC which stands for proteolysis targeting chimera.There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S.Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China — Related articles from other sources. We have checked our database to find news articles that are similar in content to the original news piece. Please find below a selection of similar news articles from other news ...Jul 13, 2021 · Dr. Tong Youzhi, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "Kintor started to build up PROTAC platform in 2018, based on which Kintor developed AR-PROTAC (GT20029), an ... This is just my advice to the guys that are depressed about hair loss, unfortunately, it’s something we can’t control (some what) I see some many young guys out here sad cause of hair loss at a young age (including me) mine started when I was 21 and had been falling off ever since (now 25) I was very self conscious about it not gonna lie but I realized that I was sad over something that ... Information regarding Kintor's GT20029. Product. 11 comments. share. save. hide. report. 94% Upvoted. Log in or sign up to leave a comment. Log In Sign Up. Sort by: best. level 1 · 12 hr. ago · edited 11 hr. ago. Don't expect too much, every time there's a pharma company that pops out and promising miracles and the end of the day 40 years ...SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic...Jul 14, 2021 · SUZHOU, China, July 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics ... Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China. Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a ...Apr 30, 2021 · Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19. Kintor Has Expanded Its Geographical Presence to Zhuhai. GT20029 IND Was Accepted by NMPA. 10 hours ago · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. Apr 15, 2021 · Developed using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the world's first topical androgen receptor (AR) compound (AR-PROTAC) to enter the clinical stage. Feb 03, 2022 · GT20029 is an a topical androgenreceptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor ... SUZHOU, China, July 13, 2021 /PRNewswire/ -- Suzhou Kintor Pharma Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne ...Jun 29, 2022 · Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826-Kintor Pharmaceutical Limited ... GT20029 IND Was ... Aug 09, 2022 · In July 2021, Kintor announced the dosing of first batch of subjects in its China phase I clinical trial of GT20029. In February 2022, Kintor announced the dosing of first subject in its US phase ... GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor ...SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic...开拓药业作为首家研发外用PROTAC药物GT20029并全球首个进入临床阶段的公司,目前正在中美两国开展GT20029治疗雄激素性脱发和痤疮的I期临床试验,并分别于2022年2月1日完成美国I期临床试验首例受试者入组给药,以及于2022年8月9日完成中国I期临床试验所有92名受试 ...Aug 09, 2022 · About GT20029. GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor pathway and its physiological function by degrading the AR protein. Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 Feb 02, 2021 · SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (the "NMPA") of China. Apr 30, 2021 · Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19. Kintor Has Expanded Its Geographical Presence to Zhuhai. GT20029 IND Was Accepted by NMPA. There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S.In Feb 2021, Kintor obtained US FDA approval to start a Ph II trial of GT90001 + Nivolumab for 2L HCC. For GT20029 (AR-degrader): The IND applications of GT20029 for androgenetic alopecia and acne vulgaris were accepted by the NMPA in Feb 2021. Maintain BUY. Considering the positive progress of Proxalutamide in treating COVID-19, we expect it ...Feb 02, 2021 · SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (the "NMPA") of China. For GT20029 (AR-degrader): The IND applications of GT20029 for androgenetic alopecia and acne vulgaris were accepted by the NMPA in Feb 2021. This is the first clinical stage PROTAC product developed by Kintor's in-house platform. ... We like Kintor given its robust pipelines including Proxalutamide, Pyrilutamide, ALK-1 antibody, PD-L1/TGF-β ...Feb 02, 2021 · On February 2, 2021, Kintor announced that an investigational new drug application (IND) for the drug GT20029 has been approved by the NMPA of China (equivalent to the FDA) for the indications of androgenic alopecia and acne vulgaris. GT20029 is a new advanced form of an anti-androgen called a PROTAC which stands for proteolysis targeting chimera. There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S.Feb 02, 2021 · On February 2, 2021, Kintor announced that an investigational new drug application (IND) for the drug GT20029 has been approved by the NMPA of China (equivalent to the FDA) for the indications of androgenic alopecia and acne vulgaris. GT20029 is a new advanced form of an anti-androgen called a PROTAC which stands for proteolysis targeting chimera. Aug 30, 2022 · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. In addition, by limiting skin penetration, GT20029 inhibits androgenetic effects locally in peripheral skin tissues, avoiding systemic effects and increasing its safety profile. Dr. Youzhi Tong,...There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S.Aug 30, 2022 · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjects for its phase I clinical trial of GT20029 in China for the treatment of androgenetic alopecia ...Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826-Kintor Pharmaceutical Limited. ... Next: GT20029 IND Was Accepted by NMPA ...Apr 15, 2021 · Developed using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the world's first topical androgen receptor (AR) compound (AR-PROTAC) to enter the clinical stage. SUZHOU, China, July 13, 2021 /PRNewswire/ -- Suzhou Kintor Pharma Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug GT20029 for treating androgenetic alopecia (AGA) and acne ...Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 To characterize the PK Cmax of GT20029 [ Time Frame: Stage 1 is about 22 days and stage 2 is about 35 days ] The plasma concentration time data for GT20029 and its metabolite will be analyzed using noncompartmental methods. Actual dosing and sampling times will be used for analyses.Jul 13, 2021 · Dr. Tong Youzhi, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "Kintor started to build up PROTAC platform in 2018, based on which Kintor developed AR-PROTAC (GT20029), an ... As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. ... Kintor Pharma's products pipeline consists of innovative, small-molecule ...Apr 30, 2021 · Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19. Kintor Has Expanded Its Geographical Presence to Zhuhai. GT20029 IND Was Accepted by NMPA. Apr 15, 2021 · Developed using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the world's first topical androgen receptor (AR) compound (AR-PROTAC) to enter the clinical stage. 10 hours ago · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. SUZHOU, China, July 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China10 hours ago · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. Aug 09, 2022 · Developed using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the world's first topical androgen receptor (AR) PROTAC compound which entered the clinical stage. GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor pathway...Feb 02, 2021 · Kintor Pharmaceutical Limited announced that the investigational new drug application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical... | August 1, 2022 开拓药业ar-protac(gt20029)获得美国fda临床试验许可-开拓药业 kintor-2021年7月13日,开拓药业有限公司(股票代码:9939.hk,以下简称:"开拓药业")欣然宣布,其自主研发的基于蛋白降解嵌合体(protac)技术开发的新型靶向雄激素受体(ar)的gt20029,已获得美国食品药品监督管理局(fda)的临床试验许可,将 ...Brief Summary. A randomized, double-blind, Placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia (AGA) or acne.Aug 30, 2022 · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. In July, Kintor Pharma announced that the first subjects had been enrolled and dosed in a phase I clinical trial of GT20029 for the treatment in AGA and acne in China. GT20029 is the world's first topical AR-PROTAC compound to enter the clinical stage. We look forward to reporting progress on pyrilutamide and GT20029 soon.Jul 13, 2021 · Dr. Tong Youzhi, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "Kintor started to build up PROTAC platform in 2018, based on which Kintor developed AR-PROTAC (GT20029), an ... As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. ... Kintor Pharma's products pipeline consists of innovative, small-molecule ...Apr 30, 2021 · Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19. Kintor Has Expanded Its Geographical Presence to Zhuhai. GT20029 IND Was Accepted by NMPA. Apr 30, 2021 · Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19. Kintor Has Expanded Its Geographical Presence to Zhuhai. GT20029 IND Was Accepted by NMPA. Aug 09, 2022 · Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China. August 9, 2022, 9:00 AM UTC. Share this article. Copied. KX-826 AND GT20029 AR DEGRADER! *INCREDIBLE*Kintor Pharma website: https://en.kintor.com.cn/Top Turke... One Of The BEST ANTI-ANDROGEN Hair Loss Companies EVER! KX-826 AND GT20029 AR DEGRADER ...Aug 09, 2022 · Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China. August 9, 2022, 9:00 AM UTC. Share this article. Copied. 开拓药业ar-protac(gt20029)治疗脱发和痤疮的美国i期临床试验完成首例受试者给药-开拓药业 kintor-2022年2月3日,开拓药业有限公司(股票代码:9939.hk,以下简称:"开拓药业")欣然宣布,其自主研发的新型靶向雄激素受体(ar)的蛋白降解嵌合体(protac)化合物gt20029治疗雄激素性脱发和痤疮的美国i期 ...Feb 02, 2021 · GT20029 will not cause excessive drug accumulation and notable side effects. While achieving efficacy, GT20029 can effectively avoid systemic exposure to mitigate or avoid the side effects of oral androgen signaling pathway inhibitors. Dr. Tong Youzhi, the founder, chairman and CEO of Kintor Pharmaceutical, commented, "The major obstacle of ... This is just my advice to the guys that are depressed about hair loss, unfortunately, it’s something we can’t control (some what) I see some many young guys out here sad cause of hair loss at a young age (including me) mine started when I was 21 and had been falling off ever since (now 25) I was very self conscious about it not gonna lie but I realized that I was sad over something that ... The first, GT20029, can effectively block the AR pathway and physiological function by degrading the AR protein. In April and July 2021, Kintor Pharma received clearance from the CDE and FDA to conduct phase I clinical trials with GT20029 for the treatment in AGA and acne in China and U.S.Mar 02, 2022 · Kintor begins dosing Phase II androgenic alopecia treatment trial in US. The change from baseline in non-vellus target area hair counts at week 24 is the primary endpoint of the trial. Kintor Pharmaceutical has dosed the first subject in the Phase II clinical trial of KX-826 (pyrilutamide) to treat male androgenetic alopecia (AGA) in the US. Suzhou, August 9, 2022 - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjects for its phase I clinical trial of GT20029 in China for the treatment of androgenetic alopecia (AGA) and acne on ...Apr 30, 2021 · Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19. Kintor Has Expanded Its Geographical Presence to Zhuhai. GT20029 IND Was Accepted by NMPA. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. ... Kintor Pharma's products pipeline consists of innovative, small-molecule ...Mar 02, 2022 · Kintor begins dosing Phase II androgenic alopecia treatment trial in US. The change from baseline in non-vellus target area hair counts at week 24 is the primary endpoint of the trial. Kintor Pharmaceutical has dosed the first subject in the Phase II clinical trial of KX-826 (pyrilutamide) to treat male androgenetic alopecia (AGA) in the US. Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (the "NMPA") of China.Feb 02, 2021 · SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic... 10 hours ago · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. Aug 30, 2022 · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. 55,6%. More Financials. Company. Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic ...Apr 30, 2021 · Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19. Kintor Has Expanded Its Geographical Presence to Zhuhai. GT20029 IND Was Accepted by NMPA. 10 hours ago · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. Aug 09, 2022 · Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China. August 9, 2022, 9:00 AM UTC. Share this article. Copied. 10 hours ago · As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. ... Kintor Pharma's products pipeline consists of innovative, small-molecule ... In July 2021, Kintor announced the dosing of first batch of subjects in its China phase I clinical trial of GT20029. In February 2022, Kintor announced the dosing of first subject in its US phase ...开拓药业作为首家研发外用PROTAC药物GT20029并全球首个进入临床阶段的公司,目前正在中美两国开展GT20029治疗雄激素性脱发和痤疮的I期临床试验,并分别于2022年2月1日完成美国I期临床试验首例受试者入组给药,以及于2022年8月9日完成中国I期临床试验所有92名受试 ...SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic...Feb 02, 2021 · SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic... Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826-Kintor Pharmaceutical Limited. ... Next: GT20029 IND Was Accepted by NMPA ...Apr 15, 2021 · Developed using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the world's first topical androgen receptor (AR) compound (AR-PROTAC) to enter the clinical stage. Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjects for its phase I clinical trial of GT20029 in China for the treatment of androgenetic alopecia ...Feb 02, 2021 · On February 2, 2021, Kintor announced that an investigational new drug application (IND) for the drug GT20029 has been approved by the NMPA of China (equivalent to the FDA) for the indications of androgenic alopecia and acne vulgaris. GT20029 is a new advanced form of an anti-androgen called a PROTAC which stands for proteolysis targeting chimera. 开拓药业ar-protac(gt20029)中国i期临床试验完成受试者入组给药-开拓药业 kintor-北京时间2022年8月9日,开拓药业(股票代码:9939.hk),一家专注于潜在同类首创和同类最佳创新药物研发及产业化的生物制药公司,今日宣布,其自主研发的新型靶向雄激素受体(ar)的蛋白降解嵌合体(protac)化合物gt20029治疗雄 ...Jun 29, 2022 · Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826-Kintor Pharmaceutical Limited ... GT20029 IND Was ... As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. ... Kintor Pharma's products pipeline consists of innovative, small-molecule ...Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 This is just my advice to the guys that are depressed about hair loss, unfortunately, it’s something we can’t control (some what) I see some many young guys out here sad cause of hair loss at a young age (including me) mine started when I was 21 and had been falling off ever since (now 25) I was very self conscious about it not gonna lie but I realized that I was sad over something that ... To characterize the PK Cmax of GT20029 [ Time Frame: Stage 1 is about 22 days and stage 2 is about 35 days ] The plasma concentration time data for GT20029 and its metabolite will be analyzed using noncompartmental methods. Actual dosing and sampling times will be used for analyses.GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor pathway...Aug 09, 2022 · About GT20029. GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor pathway and its physiological function by degrading the AR protein. In July 2021, Kintor announced the dosing of first batch of subjects in its China phase I clinical trial of GT20029. In February 2022, Kintor announced the dosing of first subject in its US phase ...KX-826 AND GT20029 AR DEGRADER! *INCREDIBLE*Kintor Pharma website: https://en.kintor.com.cn/Top Turke... One Of The BEST ANTI-ANDROGEN Hair Loss Companies EVER! KX-826 AND GT20029 AR DEGRADER ...Brief Summary. A randomized, double-blind, Placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia (AGA) or acne.Aug 09, 2022 · In July 2021, Kintor announced the dosing of first batch of subjects in its China phase I clinical trial of GT20029. In February 2022, Kintor announced the dosing of first subject in its US phase ... Find the latest Kintor Pharmaceutical Limited (9939.HK) stock quote, history, news and other vital information to help you with your stock trading and investing. ... (GT20029) in China. Kintor ...Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 开拓药业ar-protac(gt20029)获得美国fda临床试验许可-开拓药业 kintor-2021年7月13日,开拓药业有限公司(股票代码:9939.hk,以下简称:"开拓药业")欣然宣布,其自主研发的基于蛋白降解嵌合体(protac)技术开发的新型靶向雄激素受体(ar)的gt20029,已获得美国食品药品监督管理局(fda)的临床试验许可,将 ...Feb 02, 2021 · On February 2, 2021, Kintor announced that an investigational new drug application (IND) for the drug GT20029 has been approved by the NMPA of China (equivalent to the FDA) for the indications of androgenic alopecia and acne vulgaris. GT20029 is a new advanced form of an anti-androgen called a PROTAC which stands for proteolysis targeting chimera. Feb 02, 2021 · On February 2, 2021, Kintor announced that an investigational new drug application (IND) for the drug GT20029 has been approved by the NMPA of China (equivalent to the FDA) for the indications of androgenic alopecia and acne vulgaris. GT20029 is a new advanced form of an anti-androgen called a PROTAC which stands for proteolysis targeting chimera. Feb 02, 2021 · On February 2, 2021, Kintor announced that an investigational new drug application (IND) for the drug GT20029 has been approved by the NMPA of China (equivalent to the FDA) for the indications of androgenic alopecia and acne vulgaris. GT20029 is a new advanced form of an anti-androgen called a PROTAC which stands for proteolysis targeting chimera. There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S.Aug 30, 2022 · There is a huge amount of unmet clinical needs for both AGA and acne vulgaris. As the first company with an in-house topical PROTAC drug, GT20029, which has entered the clinical stage globally. Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both China and the U.S. GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor pathway...Feb 02, 2021 · SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (the "NMPA") of China. This is just my advice to the guys that are depressed about hair loss, unfortunately, it’s something we can’t control (some what) I see some many young guys out here sad cause of hair loss at a young age (including me) mine started when I was 21 and had been falling off ever since (now 25) I was very self conscious about it not gonna lie but I realized that I was sad over something that ... SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therap... 09-Aug-2022 Informative articles concerning East Asia. ... (GT20029) in China. 09-Aug-2022 Intellasia | PR Newswire Asia | 4:00 PM ...GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor pathway...Aug 09, 2022 · About GT20029. GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor pathway and its physiological function by degrading the AR protein. Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therap... 09-Aug-2022 Informative articles concerning East Asia. ... (GT20029) in China. 09-Aug-2022 Intellasia | PR Newswire Asia | 4:00 PM ...Aug 09, 2022 · About GT20029. GT20029 is a topical androgen receptor (AR) receptor degrader using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) Platform. GT20029 can effectively block the androgen receptor pathway and its physiological function by degrading the AR protein. Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA. Kintor Proxalutamide's COVID-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates. Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%.To characterize the PK Cmax of GT20029 [ Time Frame: Stage 1 is about 22 days and stage 2 is about 35 days ] The plasma concentration time data for GT20029 and its metabolite will be analyzed using noncompartmental methods. Actual dosing and sampling times will be used for analyses.GT20029 is the first topical Proteolysis Targeting Chimera (PROTAC) compound globally to have entered the clinical stage. ... Proxalutamide (Kintor Pharmecuticals), a second-generation androgen receptor antagonist, as well as HC-1119 (Hinova Pharmaceuticals), an androgen receptor inhibitor, used in COVID-19 patients are currently in phase 3 ...The GT20029 product is an androgen receptor degrader ( AR Degrader ). It is developed using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) platform. According to the press release, this is the world's first topical androgen receptor (AR) compound (AR-PROTAC) to enter clinical trials.Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China. Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a ...Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therap... 09-Aug-2022 Informative articles concerning East Asia. ... (GT20029) in China. 09-Aug-2022 Intellasia | PR Newswire Asia | 4:00 PM ...suzhou, august 9, 2022 - kintor pharmaceutical limited (“kintor pharma”, hkex: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjects for its phase i clinical trial of gt20029 in china for the treatment … Apr 30, 2021 · Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19. Kintor Has Expanded Its Geographical Presence to Zhuhai. GT20029 IND Was Accepted by NMPA. Apr 15, 2021 · Developed using Kintor's proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the world's first topical androgen receptor (AR) compound (AR-PROTAC) to enter the clinical stage. Brief Summary. A randomized, double-blind, Placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia (AGA) or acne.开拓药业ar-protac(gt20029)中国i期临床试验完成受试者入组给药 北京时间2022年8月9日,开拓药业(股票代码:9939.hk),一家专注于潜在同类首创和同类最佳创新药物研发及产业化的生物制药公司,今日宣布,其自主研发的新型靶向雄激素受体(ar)的蛋白降解嵌合体(protac)化合物gt20029治疗雄激素性脱发和 ...Kintor Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa Kintor Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne Kintor Announced U.S. FDA Has Greenlighted Phase II Clinical Trial for Pyrilutamide to Treat Androgenetic AlopeciaIn addition, by limiting skin penetration, GT20029 inhibits androgenetic effects locally in peripheral skin tissues, avoiding systemic effects and increasing its safety profile. Dr. Youzhi Tong,...Aug 11, 2022 · In February 2022, Kintor announced the dosing of first subject in its US phase I clinical trial of GT20029. About Kintor Pharmaceutical Limited Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical ... Kintor Pharma is currently conducting a phase I clinical trial of GT20029 for the treatment of AGA and acne vulgaris in both Chinaand the U.S. All 92 subjects were enrolled and dosed in the...Aug 09, 2022 · Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China. August 9, 2022, 9:00 AM UTC. Share this article. Copied. SUZHOU, China, July 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in ChinaFeb 04, 2022 · Kintor doses first subject in US Phase I trial of dermatology asset. The trial is envisioned to progress the company's footprint in androgenetic alopecia and acne. Kintor Pharmaceutical has dosed the first participant in a US Phase I clinical trial of GT20029 (gel). This is just my advice to the guys that are depressed about hair loss, unfortunately, it’s something we can’t control (some what) I see some many young guys out here sad cause of hair loss at a young age (including me) mine started when I was 21 and had been falling off ever since (now 25) I was very self conscious about it not gonna lie but I realized that I was sad over something that ... Aug 11, 2022 · In February 2022, Kintor announced the dosing of first subject in its US phase I clinical trial of GT20029. About Kintor Pharmaceutical Limited Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical ... Aug 11, 2022 · In February 2022, Kintor announced the dosing of first subject in its US phase I clinical trial of GT20029. About Kintor Pharmaceutical Limited Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical ... Feb 02, 2021 · On February 2, 2021, Kintor announced that an investigational new drug application (IND) for the drug GT20029 has been approved by the NMPA of China (equivalent to the FDA) for the indications of androgenic alopecia and acne vulgaris. GT20029 is a new advanced form of an anti-androgen called a PROTAC which stands for proteolysis targeting chimera. SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic...Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 Jul 14, 2021 · Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Wednesday, July 14, 2021 soul movie meaning of 22fastest head shaveravante laseraiken funeral home obituariessat results timevoltron x ocborn again christian dating sites freekioti ck2610 backhoeswgoh ewok counternotice to quit paanime where mc leads an armyrelate uk xo